Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Curis
Biotech
Curis aims for phase 3 as FDA lifts final hold on leukemia med
The FDA has freed Curis from a remaining partial hold, lifting the pause on a phase 1/2 leukemia study and giving the green light to the phase 2 dose.
Gabrielle Masson
Jul 6, 2023 11:33am
Curis cuts staff as pending data hint at FDA application
Nov 10, 2022 6:15am
FDA lets Curis resume enrollment for phase 1/2 leukemia study
Aug 31, 2022 7:50am
FDA lifts clinical hold on Curis' phase 1/2 lymphoma trial
Aug 18, 2022 11:23am
FDA puts Curis' leukemia trial on partial hold after death
Apr 4, 2022 8:01am
Targeting a new immune checkpoint in cancer, autoimmunity
Jan 16, 2020 2:00pm